BioSpace News Archive

Gilead and Kite Oncology Present Data Demonstrating Car T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023.

Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced a grant awarded by the Bill & Melinda Gates Foundation to support the tuberculosis (TB) test in development, designed to be run on the upcoming Co-Dx™ PCR platform*.

Wugen, Inc. will be presenting four abstracts, now available online, at the American Society of Hematology Annual Meeting and Exposition Dec. 9-12.

Umoja Biopharma, Inc. announced that its abstract, VivoVec™ Surface-Engineered Lentiviral Particles Mediate In Vivo CAR T Generation with Potent and Highly Durable Activity in Non-Human Primates and Tumor-Bearing Humanized Mice, has been selected for an oral presentation at the 65th American Society of Hematology Annual Meeting to be held December 9-12, 2023, in San Diego, California.

ADC Therapeutics SA (NYSE: ADCT) today announced abstracts on ZYNLONTA® (loncastuximab tesirine-lpyl) have been accepted for presentation at the 65th American Society of Hematology (ASH) Annual Meeting, which will be held in San Diego, California from December 9-12, 2023.

The U.S. Food and Drug Administration proposed to revoke the regulation authorizing the use of brominated vegetable oil in food.

Catalyst Pharmaceuticals, Inc. announced that the Company has received notification by the United States Patent and Trademark Office that two additional patents covering FIRDAPSE® Tablets 10 mg, were allowed and will be granted within the next two months.

RIVANNA®, developers of world-first, imaging-based medical solutions, announced they received a $2.9 million grant from the National Institutes of Health.

Ryvu Therapeutics [WSE:RVU], a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, today announced that clinical and preclinical data on RVU120, a selective CDK8/19 inhibitor, will be presented on four posters at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.

Be Biopharma, Inc. (“Be Bio”), a company pioneering the discovery and development of Engineered B Cell Medicines (BCMs) today announced that it will present new preclinical data in an oral presentation at the 65th Annual Meeting of the American Society of Hematology (ASH) taking place December 9-12, 2023, in San Diego, California.